MX356094B - Preparaciones que comprenden emodepsido amorfo. - Google Patents

Preparaciones que comprenden emodepsido amorfo.

Info

Publication number
MX356094B
MX356094B MX2014007224A MX2014007224A MX356094B MX 356094 B MX356094 B MX 356094B MX 2014007224 A MX2014007224 A MX 2014007224A MX 2014007224 A MX2014007224 A MX 2014007224A MX 356094 B MX356094 B MX 356094B
Authority
MX
Mexico
Prior art keywords
preparations containing
containing amorphous
emodepside
amorphous emodepside
preparations
Prior art date
Application number
MX2014007224A
Other languages
English (en)
Other versions
MX2014007224A (es
Inventor
Venkata-Rangarao Kanikanti
Peter Kleinebudde
Hans-Jürgen Hamann
Petra Lange
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47358491&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX356094(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of MX2014007224A publication Critical patent/MX2014007224A/es
Publication of MX356094B publication Critical patent/MX356094B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

La invención se refiere a preparaciones que comprenden emodépsido amorfo en una matriz de polivinilpirrolidona, a productos farmacéuticos que comprenden tales preparaciones y a su uso contra endoparásitos en animales o seres humanos.
MX2014007224A 2011-12-21 2012-12-18 Preparaciones que comprenden emodepsido amorfo. MX356094B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11194878 2011-12-21
PCT/EP2012/075909 WO2013092558A1 (de) 2011-12-21 2012-12-18 Zubereitungen enthaltend amorphes emodepsid

Publications (2)

Publication Number Publication Date
MX2014007224A MX2014007224A (es) 2014-09-22
MX356094B true MX356094B (es) 2018-05-14

Family

ID=47358491

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018002095A MX368209B (es) 2011-12-21 2012-12-18 Preparaciones que comprenden emodepsido amorfo.
MX2014007224A MX356094B (es) 2011-12-21 2012-12-18 Preparaciones que comprenden emodepsido amorfo.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018002095A MX368209B (es) 2011-12-21 2012-12-18 Preparaciones que comprenden emodepsido amorfo.

Country Status (24)

Country Link
US (3) US9539331B2 (es)
EP (1) EP2793861B1 (es)
JP (1) JP6185930B2 (es)
KR (2) KR101979049B1 (es)
CN (2) CN108187028A (es)
AU (2) AU2012357848C1 (es)
BR (1) BR112014014973A8 (es)
CA (1) CA2859787C (es)
CL (1) CL2014001637A1 (es)
CO (1) CO6990713A2 (es)
CR (1) CR20140293A (es)
DO (1) DOP2014000140A (es)
EC (1) ECSP14005917A (es)
ES (1) ES2734352T3 (es)
HK (1) HK1255536A1 (es)
IL (1) IL233183B (es)
MX (2) MX368209B (es)
MY (2) MY175307A (es)
NI (1) NI201400065A (es)
PH (2) PH12014501438B1 (es)
RU (2) RU2651761C2 (es)
UA (1) UA115232C2 (es)
WO (1) WO2013092558A1 (es)
ZA (1) ZA201404529B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY175307A (en) 2011-12-21 2020-06-18 Bayer Ip Gmbh Preparations comprising amorphous emodepside
CN114891070A (zh) 2015-05-20 2022-08-12 勃林格殷格翰动物保健美国公司 驱虫缩酚酸肽化合物
JP6698161B2 (ja) * 2015-12-08 2020-05-27 広州藍亮医薬科技有限公司Ｂｌｕｅｌｉｇｈｔ Ｐｈａｒｍａｔｅｃｈ Ｃｏ．，Ｌｔｄ． デコキネート固体分散体の調製方法
KR20220003663A (ko) 2015-12-28 2022-01-10 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 구충성 뎁시펩티드 화합물
MX2019005628A (es) 2016-11-16 2019-12-18 Boehringer Ingelheim Animal Health Usa Inc Compuestos depsipeptidos antihelminticos.
CN114195732A (zh) * 2022-01-04 2022-03-18 丽珠集团福州福兴医药有限公司 一种艾默德斯的单晶型iii及其制备方法
CN115444927B (zh) * 2022-09-19 2023-06-02 山东第一医科大学附属肿瘤医院(山东省肿瘤防治研究院、山东省肿瘤医院) 艾默德斯在制备治疗三阴性乳腺癌的药物中的应用
WO2025233804A1 (en) * 2024-05-07 2025-11-13 Animol Discovery, Inc. Method of treating heartworm with emodepside

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993019053A1 (en) 1992-03-17 1993-09-30 Fujisawa Pharmaceutical Co., Ltd. Depsipeptide derivative, production thereof and use thereof
DE19918325A1 (de) * 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
DE10000792A1 (de) * 2000-01-11 2001-07-19 Bernhard C Lippold Formulierungen von Wirkstoffen in Form einer festen Dispersion
DE10031044A1 (de) 2000-06-26 2002-01-03 Bayer Ag Endoparasitizide Mittel zur freiwilligen oralen Aufnahme durch Tiere
DE10358525A1 (de) * 2003-12-13 2005-07-07 Bayer Healthcare Ag Endoparasitizide Mittel zur topischen Applikation
DE102004055316A1 (de) * 2004-11-16 2006-05-18 Bayer Healthcare Ag Verhinderung vertikaler Endoparasiten-Infektionen
DE102005011779A1 (de) * 2005-03-11 2006-09-14 Bayer Healthcare Ag Endoparasitizide Mittel
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
RU2315614C1 (ru) * 2006-04-19 2008-01-27 Бийтемир Ахмедович Султанбеков Средство "грепол" и способ применения его при паразитарных заболеваниях
MX2009007482A (es) * 2007-02-09 2009-08-13 Pfizer Ltd Agentes antiparasitarios.
DE102008022520A1 (de) * 2008-05-07 2009-11-12 Bayer Animal Health Gmbh Feste Arzneimittelformulierung mit verzögerter Freisetzung
EP2355802A1 (de) * 2008-11-14 2011-08-17 Ratiopharm GmbH Intermediate und orale darreichungsformen enthaltend lenalidomid
DE102009012423A1 (de) 2009-03-10 2010-09-16 Bayer Animal Health Gmbh Zubereitung auf Ölbasis
MY175307A (en) 2011-12-21 2020-06-18 Bayer Ip Gmbh Preparations comprising amorphous emodepside

Also Published As

Publication number Publication date
JP2015502377A (ja) 2015-01-22
AU2018202376B2 (en) 2019-06-20
RU2018105003A3 (es) 2021-06-11
EP2793861A1 (de) 2014-10-29
US10251932B2 (en) 2019-04-09
US20140371139A1 (en) 2014-12-18
HK1255536A1 (zh) 2019-08-23
MY175307A (en) 2020-06-18
CN108187028A (zh) 2018-06-22
MX368209B (es) 2019-09-24
CL2014001637A1 (es) 2014-11-21
CR20140293A (es) 2014-07-14
PH12018500368A1 (en) 2018-07-23
KR20180084141A (ko) 2018-07-24
BR112014014973A2 (pt) 2017-06-13
CN104023710A (zh) 2014-09-03
US20170182118A1 (en) 2017-06-29
MY203648A (en) 2024-07-11
PH12014501438A1 (en) 2014-10-08
WO2013092558A1 (de) 2013-06-27
JP6185930B2 (ja) 2017-08-23
AU2012357848C1 (en) 2018-07-19
ECSP14005917A (es) 2015-12-31
US9539331B2 (en) 2017-01-10
NZ625817A (en) 2016-08-26
RU2014129620A (ru) 2016-02-10
UA115232C2 (uk) 2017-10-10
AU2012357848B2 (en) 2018-01-04
IL233183B (en) 2020-01-30
KR101978620B1 (ko) 2019-08-28
ES2734352T3 (es) 2019-12-05
KR20140107296A (ko) 2014-09-04
AU2012357848A1 (en) 2014-07-10
CA2859787A1 (en) 2013-06-27
BR112014014973A8 (pt) 2017-06-13
AU2018202376A1 (en) 2018-04-26
KR101979049B1 (ko) 2019-05-15
US20180153957A1 (en) 2018-06-07
ZA201404529B (en) 2017-06-28
RU2761529C2 (ru) 2021-12-09
EP2793861B1 (de) 2019-05-01
IL233183A0 (en) 2014-07-31
MX2014007224A (es) 2014-09-22
RU2651761C2 (ru) 2018-04-23
DOP2014000140A (es) 2014-07-31
CO6990713A2 (es) 2014-07-10
PH12014501438B1 (en) 2017-09-15
CA2859787C (en) 2020-09-08
NI201400065A (es) 2015-12-10
RU2018105003A (ru) 2019-02-22

Similar Documents

Publication Publication Date Title
DOP2014000140A (es) Preparaciones que comprenden emodépsido amorfo
IL282198A (en) Compositions of functional mitochondria and uses thereof
CL2014002258A1 (es) Anticuerpos dirigidos contra metaloproteinasas de matriz 9 (mmp9 gelatinasa b); composicion farmaceutica que lo contiene; y sus usos.
HUE042360T2 (hu) Izoxazolin hatóanyagot tartalmazó parazitaellenes készítmények, ezek elõállítása és alkalmazása
CL2014000467A1 (es) Formulación que comprende cepa bacteriana aislada del genero burkholderia y metabolitos plaguicidas derivados; metodo para obtener sustancia efectiva como plaguicida derivada de la formulación antes indicada.
CL2014000370A1 (es) Hemifumarato de tenofovir alafenamida; metodo de preparación; composicion farmaceutica que lo comprende; metodo para preparar la composicion farmaceutica; y uso en el tratamiento de una infeccion por hiv.
GT201200304A (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
BR112015023417A2 (pt) compostos heterocíclicos e seus usos
IL216006A (en) Substituted aromatic compounds, pharmaceutical compositions comprising them and use thereof in the manufacture of medications
BR112012032008A2 (pt) anticorpos s100a4 e usos terapêuticos do mesmo
PT2739615T (pt) Fenil-3-aza-biciclo[3.1.0]hex-3-il-metanonas e a sua utilização como medicamento
CL2014002348A1 (es) Compuestos derivados de fenicol; composicion farmaceutica que los comprende; y su uso para controlar o tratar infecciones bacterianas en ganado.
GB201215159D0 (en) Composition
CL2014003472A1 (es) Pro-farmacos derivados de (e)-n-metil-n-((3-metilbenzofuran-2-il)metil)-3-(7-oxo-5,6,7,8-tetrahidro-1,8-naftiridin-3-il)acrilamida; composicion farmaceutica que los comprende; y su uso para tratar una infeccion bacteriana.
CR20150266A (es) Formulaciones de liberación modificada para oprozomib
IT1398268B1 (it) Glicerosomi e loro impiego in preparazioni farmaceutiche e cosmetiche per uso topico
BR112013019687A2 (pt) antraquinona contendo preparações/formulações de lignina.
EP3068436A4 (en) Topical pharmaceutical, cosmetic and disinfectant compositions comprising phosphatidylcholine
BR112013023575A2 (pt) “derivado de octaidrotienoquinolina, composição farmacêutica compreendendo o derivado, e uso destes”
MX2014006574A (es) Formulaciones de acamprosato, metodos de uso de las mismas, y combinaciones que comprenden las mismas.
PH12013501552A1 (en) Oral care compositions
EP2899198A4 (en) SYNTHETIC PNTX (19) -EPEPTIDES, PHARMACEUTICAL COMPOSITIONS AND USES
CU20130041A7 (es) Micobacteria recombinante como vacuna contra la tuberculosis para uso en humanos
EP2789613A4 (en) 1,4-DIHYDRO-NAPHTHYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF AND ITS USE
BR112013010061A2 (pt) "composição farmacêutica, composição e uso"

Legal Events

Date Code Title Description
FG Grant or registration
PD Change of proprietorship

Owner name: BAYER PHARMA AKTIENGESELLSCHAFT.*